Extended Data Fig. 3: Grade ≥ 3 Adverse events.
From: Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
a) Grade ≥ 3 adverse events that occurred in at least 5 patients. b) Grade 5 adverse events. Each line reports a different event. SoC: standard of care, TT: tailored treatment; CTCAE: Common Terminology Criteria for Adverse Events.
